Reversal agents for dabigatran-, edoxaban- and betrixaban-related major bleeding or a required urgent procedure
| DOAC | Reversal agent dosing |
|---|---|
| Dabigatran | Idarucizumab 5 g intravenously (IV) If idarucizumab is not available, the alternative treatment recommended is activated prothrombin complex concentrate 50 units/kg IV (off-label use) |
| Edoxaban, betrixaban | Andexanet alfa 800 mg IV bolus at 30 mg/minute followed by continuous infusion of 8 mg/minute for up to 120 minutes (off-label use) or 4-factor prothrombin complex concentrate 2,000 units IV |